Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
DIAGNOSTIC UTILITY OF TOMOGRAPHIC MYOCARDIAL PERFUSION IMAGING WITH TECHNETIUM 99M FURIFOSMIN (Q12) COMPARED WITH THALLIUM-201 - RESULTS OFA PHASE-III MULTICENTER TRIAL
Autore:
HENDEL RC; VERANI MS; MILLER DD; WACKERS FJT; MCMAHON M; CERQUEIRA MD; BOTVINICK EH; KVOLS L; GERSON MC;
Indirizzi:
NORTHWESTERN UNIV,SCH MED,250 E SUPER ST,SUITE 456 CHICAGO IL 60611 BAYLOR COLL MED HOUSTON TX 77030 ST LOUIS UNIV,MED CTR ST LOUIS MO 00000 MALLINCKRODT MED INC ST LOUIS MO 00000 YALE UNIV,SCH MED NEW HAVEN CT 00000 UNIV WASHINGTON,MED CTR SEATTLE WA 98195 UNIV CALIF SAN FRANCISCO SAN FRANCISCO CA 94143 UNIV CINCINNATI,MED CTR CINCINNATI OH 45267
Titolo Testata:
Journal of nuclear cardiology
fascicolo: 4, volume: 3, anno: 1996,
pagine: 291 - 300
SICI:
1071-3581(1996)3:4<291:DUOTMP>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORONARY-ARTERY-DISEASE; METHOXY ISOBUTYL ISONITRILE; 2-METHOXYISOBUTYL ISONITRILE; HUMAN BIODISTRIBUTION; NUCLEAR CARDIOLOGY; KINETIC-PROPERTIES; CANINE MYOCARDIUM; MEDICAL PROGRESS; TL-201; STRESS;
Keywords:
RADIONUCLIDE; IMAGING DIAGNOSIS; FURIFOSMIN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
39
Recensione:
Indirizzi per estratti:
Citazione:
R.C. Hendel et al., "DIAGNOSTIC UTILITY OF TOMOGRAPHIC MYOCARDIAL PERFUSION IMAGING WITH TECHNETIUM 99M FURIFOSMIN (Q12) COMPARED WITH THALLIUM-201 - RESULTS OFA PHASE-III MULTICENTER TRIAL", Journal of nuclear cardiology, 3(4), 1996, pp. 291-300

Abstract

Background. Based on physical properties, Tc-99m-labeled perfusion agents offer several advantages over Tl-201 for myocardial perfusion imaging. The results of in vivo and experimental studies, along with preliminary experience in human subjects, have shown Tc-99m-labeled furifosmin to be a promising new perfusion tracer. The purpose of this studywas to evaluate the safety of a new myocardial perfusion agent, Tc-99M-labeled furifosmin (Q12), and determine the concordance of furifosmin perfusion scintigraphy to Tl-201 imaging. In addition, we sought to determine the normalcy rate of myocardial scintigraphy with furifosmin. Methods and Results. One hundred fifty patients constituted the study group in this multicenter trial. Patients underwent exercise testingwith furifosmin injected at peak exercise, and tomographic imaging was begun 15 to 30 minutes afterward. After a separate injection, resting images were obtained 3 to 4 hours later. Thallium scintigraphy was performed within 2 weeks of the furifosmin scans, after a similar exercise workload. Patients with a low likelihood of coronary artery disease (n = 39) also underwent furifosmin imaging. All images were processed and displayed in uniform manner and interpreted by a panel of readers. No adverse effects or clinically important laboratory alterations were related to furifosmin imaging. Image quality was slightly better with furifosmin than with thallium. The overall concordance between theperfusion studies was 86% (kappa value = 0.669). The normalcy rate for furifosmin scintigraphy was 100%, Conclusions. Tc-99m-labeled furifosmin is a promising new Tc-99m-labeled myocardial perfusion agent, providing diagnostic results similar to those obtained with Tl-201.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 10:04:53